BioSpace News Archive

Antios Therapeutics, Inc. (“Antios”) today announced that Douglas Mayers , M.D., Chief Medical Officer and Co-Founder of Antios, will be giving a presentation on ATI-2173 at the International Coalition to Eliminate HBV (ICE-HBV) Toronto Annual Symposium in conjunction with the International HBV Meeting on September 30, 2021.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced the participation of its management team at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.

Erasca, Inc. announced dosing of the first patient in HERKULES-3, a Phase 1b/2 master protocol clinical trial evaluating ERAS-007 in combination with various agents in patients with gastrointestinal cancer, with initial focus on patients with advanced colorectal cancer.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Thermo Scientific NanoDrop Eight UV-Vis Microvolume Spectrophotometer, a robust, easy-to-use spectrophotometer that replaces the NanoDrop 8000.

Vividion Therapeutics, Inc. today announced the formation of a scientific advisory board (SAB) comprised of industry leaders in oncology, immunology, drug development and chemical biology.

Equillium, Inc today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 – 30, 2021.

Peptilogics will present first-in-human Phase 1 data on its lead investigational therapy PLG0206

KSQ Therapeutics today announced that Qasim Rizvi, Chief Executive Officer of KSQ, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 4:40 PM (ET).

Theratechnologies Inc. is pleased to announce that a study evaluating an intravenous (IV) push form of administration of Trogarzo

World leader in research and clinical treatment of age-related cognitive and functional decline to maximize human performance, Aviv Scientific, announces the closing of $40 million in a oversubscribed Series B funding round.